Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

HORSHOLM, Denmark, July 14 /PRNewswire/ -- The Board of Directors of Santaris Pharma has approved the Interim Report for the period 1 January to 30 June 2009.

    - The loss after tax realised in the 2nd quarter of 2009 was
      21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd
      quarter of 2008.

    - As at June 30, 2009 the capital resources totalled 175,4m
      DKK (23,6m EUR).

    - In Q2 the SPC3649 compound targeting hepatitis C finalized a
      single dose First/In/Man study with encouraging results and a multiple
      ascending dose study in healthy volunteers is scheduled to commence in
      Q3 2009.

    - Santaris Pharma's new lead candidate SPC4955 targeting
      apoliproteinB, the major cholesterol carrying protein in the blood, has
      been selected for preclinical trials.

    - Lead candidates targeting PCSK9, which is known to play a
      critical role in regulating cholesterol levels, have been selected for
      pharmacological studies.

    - The Collaboration with the Company's 3rd partner, Wyeth, was
      initiated during the first months of 2009 and is progressing according
      to the plan.


    (Logo:http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

During the first half of 2009 Santaris Pharma continued to make satisfactory progress in its research and development programs within miRNA, metabolic disorders and infectious diseases. Key milestones achieved and other events during the quarter are summarized below.

Development

SPC3649-HCV

SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and t
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Rust removal is one of home maintenance's ... could be damaged. To help rust contractors make it less ... rust remover it called Rusterizer. It announced that ... discount. , My Cleaning Products explained that rust could damage ... staining them. The first one, it said, happens when ...
(Date:5/16/2013)... Oven Industries, Inc. has been an industry leader ... since 1964. Expertly designed, the proportional-integral-derivative PID temperature ... As one of the most commonly used ... feedback system, which helps minimize errors. With three-term control, ... process, using a control element, like a valve or ...
(Date:5/16/2013)... , May 16, 2013  HealthSparq, a trusted ... the nation,s largest regional health plans, will debut ... Insurance Plans (AHIP) Institute 2013 conference on June ... results showing how health insurance companies across the ... consumer and marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... , May 16, 2013 ... research report is available in its ... Competitor Analysis: Therapeutic Proteins – ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ... The new Competitive Intelligence ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2New PID Temperature Controllers Announced by Oven Industries Inc. 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8
... a professor of electrical and computer engineering and Director ... California, Santa Barbara, has been named winner of the ... (ESDA). "The ESDA research award is ... ideas that advance the field of electrostatic discharge. Professor ...
... 2011 Molecular diagnostics company GenturaDx announced the ... appointment of three initial members: Dr. Keith Jerome, ... Dr. Gregory Tsongalis, Ph.D., H.C.L.D., F.A.C.B. The board ... and the commercial market related to initial test ...
... PRA, a leading Clinical Research Organization, announces that ... group will speak at VIBPharma,s 7th Annual Pharmacovigilance, Drug ... Belgium from 22-23 November 2011.  PRA will also host ... will be available to discuss PRA,s approach to pharmacovigilance. ...
Cached Biology Technology:UCSB professor receives award for graphene electronics research 2GenturaDx Announces Formation of Scientific Advisory Board 2PRA Expert to Present at Pharmacovigilance Conference 2
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... trigger hematopoiesis at sites outside the bone marrow ... Ludwig-Maximilians-Universitaet (LMU) in Munich now show that a specific ... of blood cells. , Balanced hematopoiesis is essential for ... hematopoiesis takes place mainly in the liver and the ... marrow, and this tissue normally serves as the sole ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... of pigmentation patterns on mollusk seashellswhich could aid ... to be a challenging feat for researchers. Now, ... Pittsburgh and University of California, Berkeley, researchers have ... snail Conus to generate a model ...
... goes the cynical saying with television and newspaper editors. In other ... the big story on the front page. So one might ... and unhappy types of words like "war," " funeral," "cancer," ... "hero." Or take Twitter. A popular image of what people ...
... 2012: A research collaboration between the Wyss Institute ... Children,s Hospital Boston has developed "smart" injectable nanotherapeutics ... to the cells of the pancreas. Although this ... before being ready for clinical use, it could ...
Cached Biology News:Breakthrough model reveals evolution of ancient nervous systems through seashell colors 2We may be less happy, but our language isn't 2We may be less happy, but our language isn't 3New 'smart' nanotherapeutics can deliver drugs directly to the pancreas 2